Company Presentation

Working towards safer, easier to administer and strong long-lasting immunotherapies, Gnubiotics has developed the GLAAD (glycopeptides with adjuvant and tumor-associated antigen delivery) technology, that leverages principles of glyco-immunology and microbiology with the goal to steer an immune response directed against the specific solid tumor types.